SCHEMBL4597640

SCHEMBL4597640

CCCCCN1C(=O)C(=O)c2ccc(Cl)cc21

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.64
ALDH2 P05091 2/20 0.64
ALDH3A1 P30838 2/20 0.64
CES1 P23141 2/20 0.62
CDC25A P30304 1/20 0.62
APAF1 O14727 1/20 0.53
CNR2 P34972 1/20 0.45
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRA6 Q16445 1/20 0.45
PTGS1 P23219 3/20 0.44
PTGS2 P35354 3/20 0.44
MGLL Q99685 2/20 0.44
FAAH O00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16366714 0.88 ALDH1A1 (0.64) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL3025055 0.87 CES1 (0.65) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL29011250 0.85 APAF1 (0.53) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL29011256 0.84 APAF1 (0.52) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL29011251 0.84 APAF1 (0.55) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL16046979 0.84 ALDH1A1 (0.62) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL29411355 0.83 APAF1 (0.60) ALDH1A1ALDH2ALDH3A1CES1APAF1
SCHEMBL28417285 0.81 CES1 (0.65) ALDH1A1ALDH2ALDH3A1CES1CDC25A
SCHEMBL29220369 0.80 CES1 (0.61) ALDH1A1ALDH2ALDH3A1CES1APAF1
SCHEMBL3009244 0.80 ALDH1A1 (0.61) ALDH1A1ALDH2ALDH3A1CES1CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008046083-A2 USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-04-17 WO disclosed
EP-1877378-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-01-16 EP disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
WO-2006113864-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents OPRL1, OPRK1, TRPV1 ALDH1A1 1136/4885ALDH2 720/4885ALDH3A1 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.